Table 4.
Clinical and biochemical parameters at baseline and at week 12 of liraglutide treatment
| Items | Mean value ± SD | n | Change (SE) | p value | |
|---|---|---|---|---|---|
| Baseline | Week 12 | ||||
| Weight (kg) | 73.9 ± 17.0 | 72.5 ± 16.7 | 204 | −1.4 (0.3) | <0.001 |
| BMI (kg/m2) | 27.9 ± 5.3 | 27.3 ± 5.2 | 203 | −0.5 (0.1) | <0.001 |
| Systolic blood pressure (mmHg) | 131.1 ± 15.4 | 129.4 ± 16.0 | 203 | −1.8 (1.2) | 0.134 |
| Diastolic blood pressure (mmHg) | 76.0 ± 11.6 | 76.4 ± 12.2 | 203 | 0.4 (0.8) | 0.652 |
| HbA1c (NGSP, %) | 8.7 ± 1.5 | 7.5 ± 1.3 | 203 | −1.2 (0.1) | <0.001 |
| Random blood glucose level (mg/dL) | 199 ± 80 | 170 ± 66 | 198 | −29.0 (5.8) | <0.001 |
| RBCs (×104/μL) | 459 ± 54 | 458 ± 50 | 135 | −1.1 (2.5) | 0.661 |
| WBCs (/mm3) | 6887 ± 1879 | 6913 ± 1876 | 135 | 26.4 (140.4) | 0.851 |
| Hemoglobin (g/dL) | 13.9 ± 1.6 | 13.9 ± 1.5 | 135 | 0.0 (0.1) | 0.886 |
| Hematocrit (%) | 41.6 ± 4.2 | 41.8 ± 4.2 | 135 | 0.2 (0.2) | 0.225 |
| Blood platelets (×104/μL) | 22.5 ± 6.2 | 23.1 ± 5.7 | 134 | 0.6 (0.4) | 0.088 |
| AST (IU/L) | 28.1 ± 20.6 | 26.6 ± 19.3 | 162 | −1.5 (1.1) | 0.176 |
| ALT (IU/L) | 36.1 ± 33.1 | 33.5 ± 29.0 | 160 | −2.7 (1.6) | 0.090 |
| γGTP (IU/L) | 50.0 ± 52.7 | 50.2 ± 64.8 | 153 | 0.2 (2.9) | 0.943 |
| Serum creatinine (mg/dL) | 0.9 ± 1.0 | 0.9 ± 0.9 | 162 | 0.0 (0.0) | 0.215 |
| Uric acid (mg/dL) | 5.6 ± 1.5 | 5.4 ± 1.4 | 151 | −0.2 (0.1) | 0.025 |
| TC (mg/dL) | 189.1 ± 36.5 | 180.8 ± 32.2 | 117 | −8.4 (2.8) | 0.003 |
| HDL-C (mg/dL) | 50.9 ± 12.9 | 49.7 ± 12.5 | 155 | −1.2 (0.6) | 0.041 |
| TG (mg/dL) | 177.9 ± 130.3 | 172.3 ± 100.8 | 166 | −5.6 (7.4) | 0.451 |
BL baseline, w12 week 12, RBCs red blood cells, WBCs white blood cells, BMI body mass index HbA1c hemoglobin A1c, NGSP National Glycohemoglobin Standardization Program, AST aspartate aminotransferase, ALT alanine aminotransferase, γGTP γ-glutamyl transpeptidase, TC total cholesterol, HDL-C high density lipoprotein cholesterol, TG triglyceride
p values are the results of paired t test